Boehringer to invest $268 million in new biologics facility

22 June 2018

Privately-held German pharma major Boehringer Ingelheim has announced its intention to invest 230 million euros ($268 million) into a new Biologics Development Center (BDC) at its existing research site in Biberach, Germany.

The new BDC will serve to streamline the discovery and development of biologics by allowing more of the process to take place at one location, while at the same time increasing development capacity. Beginning with a staggered launch in 2020, the new building will see 100 more jobs created at the facility.

This is the latest of many recent expenditures for Boeringher. The company has also pledged to build new facilities in Vienna and Shanghai as well as to expand its existing setup in Fremont, California.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK